1 / 15

Imbruvica 140mg | Imbruvica 140mg capsules | Ibrutinib 140mg | Ibrutinib 140mg capsules

Imbruvica stops a protein in B cells called Brutonu2019s tyrosine kinase, or BTK. BTK indicating <br>is required for B cells to multiply and survive.

Emimadi
Download Presentation

Imbruvica 140mg | Imbruvica 140mg capsules | Ibrutinib 140mg | Ibrutinib 140mg capsules

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Imbruvica 140mg capsules Apple pharmaceuticals

  2. Imbruvica 140mg capsules • IMBRUVICA stops a protein in B cells called Bruton’s tyrosine kinase, or BTK. BTK indicating is required for B cells to multiply and survive.  • Imbruvica140mg may help progress abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs. 

  3. INDICATION • Mantle cell lymphoma (MCL) who have getting at least one prior treatment •  Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL) • • Marginal zone lymphoma (MZL) who getting a medicine by mouth or injection (systemic therapy) and have getting a certain type of before treatment

  4. • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy • Waldenströmmacroglobulinemia (WM) • • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy •  Marginal zone lymphoma (MZL) who getting a medicine by mouth or injection 

  5. ADME • Peak plasma concentration of Imbruvica is 1-2 hours and drug taking with food will increasesibrutinibexposure. • Imbruvica has plasma protein level is 97.3% and Vd is 10,000L • Ibrutinib was excretion through feces 80% and urine 10 % Half-life of ibrutinib is 4-6 hours

  6. DOSAGE Lymphoma: • The recommended dose of patient is 420mg (three 140mg capsules) per oral qday • While in combination with bendamustine and rituximab the usual dose is 420mg PO qDay administrated q28d for up to 6 cycles until progression or undesirable toxicity

  7. Mantle Cell Lymphoma: • The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay. • Follow until disease progression or undesirable toxicity • Marginal Zone Lymphoma : • The recommended dose of patientis 560mg (four 140mg-mg capsules) PO qDay. • Follow until disease progression or undesirable toxicity

  8. WaldenströmMacroglobulinemia: • The recommended dose of patient is 420mg (three 140mg capsules) per oral qDay • When combination with rituximab is 420 mg PO qDay plus rituximab administered weekly for 4 consecutive weeks (weeks 1-4)  • continued by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20)

  9. MECHANISM • Ibrutinib 140mg belongs to type of small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. •  Nonclinical studies revealwhichibrutinib prohibits malignant B-cell multiplication and survival in vivo as well as cell migration and substrate adhesion in vitro.

  10. PRECAUTION • Other malignancies (5-14%) resulted contains carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma skin cancer (4-11%)  • Tumor lysis syndrome intermittentlyresulted; assess the baseline risk (eg, high tumor burden) and take suitable precautions  • Based on findings in animals, can cause fetal risk when administered to a pregnant woman 

  11. DRUG INTERACTION • When Co administration of imbruvica 140mg with strong or moderate CYP3A inhibitor will increase ibrutinib plasma concentrations along with have high risk of drug related toxicity • When Co administration ofimbruvica 140mg with strong or moderate CYP3A inducers will decreaseibrutinib plasma concentrations.

  12. CONTRAINDICATION • Hypersentivityreaction MISSED DOSE • If dose is missed, thereby missed dose should be avoid and follow the regular dosing schedule. • Patients must consult with medical practitioner and follow the instructions given by them.

  13. SIDE EFFECTS More common side effects of Imbruvica 140mg : • Low platelets • Musculoskeletal pain • Swelling • Upper respiratory tract infection • Nausea • Diarrhea • Reduced neutrophils • Decreased haemoglobin • Fatigue • Bruising. 

  14. More common side effects of Imbruvica 140mg : • Skin infections • Asthenia • Muscle spasms • Shortness of breath • Constipation • Rash • Sinusitis • Headache • Dehydration • Dyspepsia • Abdominal pain • Vomiting • Decreased appetite

  15. CONTACT USphone No      : 9987711567Email             : Info@myapplepharma.comWEBSITEMYAPPLEPHARMAIBRUTINIB 140MG CAPSULES

More Related